Skin barrier dysfunction and correlation with the onset and progression of psoriasis

• by Ying Wang, Yanyang Liang, Jianxiao Xing, Junqin Li, Kaiming Zhang

• June 30, 2026

Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse

• by Jingyi Ma, Haoyu Li, Xueqi Yang, Yuzhe Cheng, Bingran Qi, Siyu Kang, He Qi, Ruiqun Qi, Jun Niu

• May 15, 2026

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.

• by Kathryn Wighton

• June 29, 2026

• 3 min

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial

• by Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Hiram Ruiz-Santiago, Kilian Eyerich, Mar Llamas-Velasco, Michael Bukhalo, Raja K. Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren

• May 17, 2026